ROCKVILLE, Md., June 13 /PRNewswire-FirstCall/ -- EntreMed, Inc.(Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeuticsfor the treatment of cancer and inflammatory diseases, announced today thatJames S. Burns, President and Chief Executive Officer, will present a Companyoverview during the Business Forum at the Biotechnology Industry Organization2008 Annual International Convention, being held June 17-20, 2008 at the SanDiego Convention Center, San Diego, California. Mr. Burns' presentation isscheduled for Wednesday, June 18, 2008 at 1:00 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' presentation will not be web cast, however the presentation canbe accessed through the Company's web site at www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developingtherapeutic candidates primarily for the treatment of cancer and inflammation.MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is anoral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, anovel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are inPhase 1 studies in advanced cancers. The Company also has an approved INDapplication for Panzem(R) in rheumatoid arthritis. EntreMed's goal is todevelop and commercialize new compounds based on the Company's expertise inangiogenesis, cell-cycle regulation and inflammation - processes vital to thetreatment of cancer and other diseases, such as rheumatoid arthritis.Additional information about EntreMed is available on the Company's web siteat www.entremed.com and in various filings with the Securities and ExchangeCommission.

    CONTACT:    Ginny Dunn    Associate Director    Corporate Communications &    Investor Relations    EntreMed, Inc.    240-864-2643

SOURCE EntreMed, Inc.